David Low

In a report published Thursday, Deutsche Bank analyst David Low downgraded the rating on ResMed (NYSE: RMD) from Buy to Hold, but reiterated the $52.00 price target. In the report, Deutsche Bank noted, “The Centers for Medicare & Medicaid Services (CMS) has issued a release to update among...

In a report published Friday, Deutsche Bank Markets Research analyst David Low downgraded ResMed Inc. (NYSE: RMD) from Buy to Hold and maintained their $54 PT based on a disappointing sales forecast. Although the medium term outlook remains positive, ResMed suffered market share pressure from...

In a report published Friday, Deutsche Bank analyst David Low upgraded ResMed (NYSE: RMD) from Hold to Buy, and raised the price target from $46.00 to $54.00. In the report, Deutsche Bank noted, “While the impact of competitive bidding won't be clear for some time, the solid Q4 result was...

In a report published Thursday, Deutsche Bank analyst David Low reiterated a Hold rating on ResMed (NYSE: RMD), and raised the price target from $45.00 to $46.00. In the report, Deutsche Bank noted, “While industry feedback on the impact of the large Competitive Bidding funding cuts remains...